No association between Parkinson disease and autoantibodies against NMDA-type glutamate receptors.

TitelNo association between Parkinson disease and autoantibodies against NMDA-type glutamate receptors.
MedientypJournal Article
Jahr der Veröffentlichung2019
AutorenHopfner F, Müller SH, Steppat D, Miller J, Schmidt N, Wandinger K-P, Leypoldt F, Berg D, Franke A, Lieb W, Tittmann L, Balzer-Geldsetzer M, Baudrexel S, Dodel R, Hilker-Roggendorf R, Kalbe E, Kassubek J, Klockgether T, Liepelt-Scarfone I, Mollenhauer B, Neuser P, Reetz K, Riedel O, Schulte C, Schulz JB, Spottke A, Storch A, Trenkwalder C, Wittchen H-U, Witt K, Wüllner U, Deuschl G, Kuhlenbäumer G
JournalTransl Neurodegener
Volume8
Pagination11
Datum der Veröffentlichung2019
ISSN2047-9158
Zusammenfassung

<p><b>Background: </b>IgG-class autoantibodies to N-Methyl-D-Aspartate (NMDA)-type glutamate receptors define a novel entity of autoimmune encephalitis. Studies examining the prevalence of NMDA IgA/IgM antibodies in patients with Parkinson disease with/without dementia produced conflicting results. We measured NMDA antibodies in a large, well phenotyped sample of Parkinson patients without and with cognitive impairment ( = 296) and controls ( = 295) free of neuropsychiatric disease. Detailed phenotyping and large numbers allowed statistically meaningful correlation of antibody status with diagnostic subgroups as well as quantitative indicators of disease severity and cognitive impairment.</p><p><b>Methods: </b>NMDA antibodies were analysed in the serum of patients and controls using well established validated assays. We used anti-NMDA antibody positivity as the main independent variable and correlated it with disease status and phenotypic characteristics.</p><p><b>Results: </b>The frequency of NMDA IgA/IgM antibodies was lower in Parkinson patients (13%) than in controls (22%) and higher than in previous studies in both groups. NMDA IgA/IgM antibodies were neither significantly associated with diagnostic subclasses of Parkinson disease according to cognitive impairment, nor with quantitative indicators of disease severity and cognitive impairment. A positive NMDA antibody status was positively correlated with age in controls but not in Parkinson patients.</p><p><b>Conclusion: </b>It is unlikely albeit not impossible that NMDA antibodies play a significant role in the pathogenesis or progression of Parkinson disease e.g. to Parkinson disease with dementia, while NMDA IgG antibodies define a separate disease of its own.</p>

DOI10.1186/s40035-019-0153-0
Alternate JournalTransl Neurodegener
PubMed ID30984390
PubMed Central IDPMC6446289